April 2024
1. BUTLER J, Shah SJ, Petrie MC, Borlaug BA, et al
   Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials.
   Lancet. 2024 Apr 4:S0140-6736(24)00469-0. doi: 10.1016/S0140-6736(24)00469.
   

   >> Share

   
   
2. DONAL E, L'Official G, Istratoaie S
   Semaglutide-a new treatment for obesity-related heart failure with preserved ejection fraction?
   Lancet. 2024 Apr 4:S0140-6736(24)00653-6. doi: 10.1016/S0140-6736(24)00653.
   

   >> Share

   
   March 2024
3. KIKOINE J, Kilani N, Pitta-Gros B, Yerly P, et al
   Remote haemodynamic monitoring in patients with heart failure.
   Lancet. 2024;403:808.
   

   >> Share

   
   
4. BRUGTS JJ, Aydin D, Clephas PRD, de Boer RA, et al
   Remote haemodynamic monitoring in patients with heart failure - Authors' reply.
   Lancet. 2024;403:808-809.
   

   >> Share

   
   
5. KOMAMURA K, Iwase M
   Remote haemodynamic monitoring in patients with heart failure.
   Lancet. 2024;403:807-808.
   

   >> Share

   
   February 2024
6. CAMPBELL P, Rutten FH, Lee MM, Hawkins NM, et al
   Heart failure with preserved ejection fraction: everything the clinician needs to know.
   Lancet. 2024 Feb 14:S0140-6736(23)02756-3. doi: 10.1016/S0140-6736(23)02756.
   

   >> Share

   
   November 2023
7. KHAN Y, Verhaeghe N, Devleesschauwer B, Cavillot L, et al
   Impact of the COVID-19 pandemic on delayed care of cardiovascular diseases in Europe: a systematic review.
   Lancet. 2023;402 Suppl 1:S61.
   

   >> Share

   
   August 2023
8. WILKOFF BL, Filippatos G, Leclercq C, Gold MR, et al
   Adaptive versus conventional cardiac resynchronisation therapy in patients with heart failure (AdaptResponse): a global, prospective, randomised controlled trial.
   Lancet. 2023 Aug 24:S0140-6736(23)00912-1. doi: 10.1016/S0140-6736(23)00912.
   

   >> Share

   
   May 2023
9. ANGERMANN CE
   Remote pulmonary artery pressure monitoring in heart failure care: part of the new normal?
   Lancet. 2023 May 19:S0140-6736(23)01010-3. doi: 10.1016/S0140-6736(23)01010.
   

   >> Share

   
   
10. BRUGTS JJ, Radhoe SP, Clephas PRD, Aydin D, et al
    Remote haemodynamic monitoring of pulmonary artery pressures in patients with chronic heart failure (MONITOR-HF): a randomised clinical trial.
    Lancet. 2023 May 19:S0140-6736(23)00923-6. doi: 10.1016/S0140-6736(23)00923.
    

    >> Share

    
    April 2023
11. SCHLAICH MP, Bellet M, Weber MA, Bakris GL, et al
    Fluid retention and heart failure in the PRECISION trial - Authors' reply.
    Lancet. 2023;401:1335-1336.
    

    >> Share

    
    
12. KOHAN DE, Heerspink HJL
    Fluid retention and heart failure in the PRECISION trial.
    Lancet. 2023;401:1335.
    

    >> Share

    
    March 2023
13. HE J, Ouyang N, Guo X, Sun G, et al
    Effectiveness of a non-physician community health-care provider-led intensive blood pressure intervention versus usual care on cardiovascular disease (CRHCP): an open-label, blinded-endpoint, cluster-randomised trial.
    Lancet. 2023 Mar 2:S0140-6736(22)02603-4. doi: 10.1016/S0140-6736(22)02603.
    

    >> Share

    
    November 2022
14. MCDONAGH TA, Bromage DI, Cannata A
    Intravenous iron passes another endurance test in heart failure.
    Lancet. 2022 Nov 4. pii: S0140-6736(22)02180.
    

    >> Share

    
    
15. KALRA PR, Cleland JGF, Petrie MC, Thomson EA, et al
    Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial.
    Lancet. 2022 Nov 4. pii: S0140-6736(22)02083.
    

    >> Share

    
    
16. MEBAZAA A, Davison B, Chioncel O, Cohen-Solal A, et al
    Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial.
    Lancet. 2022 Nov 4. pii: S0140-6736(22)02076.
    

    >> Share

    
    
17. 
    Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials.
    Lancet. 2022 Nov 4. pii: S0140-6736(22)02074.
    

    >> Share

    
    August 2022
18. VADUGANATHAN M, Docherty KF, Claggett BL, Jhund PS, et al
    SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials.
    Lancet. 2022 Aug 26. pii: S0140-6736(22)01429.
    

    >> Share

    
    
19. TUTTLE KR, Rangaswami J
    SGLT2 inhibitors as the bedrock of therapy for heart failure.
    Lancet. 2022 Aug 26. pii: S0140-6736(22)01584.
    

    >> Share

    
    
20. CARTELLA I, Tavecchia GA, Quattrocchi G, Giannattasio C, et al
    A heart of iron: juvenile haemochromatosis presents with cardiac failure.
    Lancet. 2022;400:616.
    

    >> Share

    
    April 2022
21. BECK-DA-SILVA L, Rohde LE
    Reduction of dietary sodium for heart failure: a step forward.
    Lancet. 2022;399:1361-1363.
    

    >> Share

    
    
22. EZEKOWITZ JA, Colin-Ramirez E, Ross H, Escobedo J, et al
    Reduction of dietary sodium to less than 100 mmol in heart failure (SODIUM-HF): an international, open-label, randomised, controlled trial.
    Lancet. 2022;399:1391-1400.
    

    >> Share

    
    January 2022
23. SHAH SJ, Borlaug BA, Chung ES, Cutlip DE, et al
    Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): a randomised, multicentre, blinded, sham-controlled trial.
    Lancet. 2022 Jan 31. pii: S0140-6736(22)00016.
    

    >> Share

    
    August 2021
24. KARWATH A, Bunting KV, Gill SK, Tica O, et al
    Redefining beta-blocker response in heart failure patients with sinus rhythm and atrial fibrillation: a machine learning cluster analysis.
    Lancet. 2021 Aug 27. pii: S0140-6736(21)01638.
    

    >> Share

    
    
25. LINDENFELD J, Zile MR, Desai AS, Bhatt K, et al
    Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial.
    Lancet. 2021 Aug 26. pii: S0140-6736(21)01754.
    

    >> Share

    
    
26. CLELAND JGF, Pellicori P
    To master heart failure, first master congestion.
    Lancet. 2021 Aug 26. pii: S0140-6736(21)01914.
    

    >> Share

    
    
27. 
    Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis.
    Lancet. 2021 Aug 26. pii: S0140-6736(21)01921.
    

    >> Share

    
    July 2021
28. BROWN E, Heerspink HJL, Cuthbertson DJ, Wilding JPH, et al
    SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications.
    Lancet. 2021;398:262-276.
    

    >> Share

    
    May 2021
29. 
    Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis.
    Lancet. 2021;397:1625-1636.
    

    >> Share

    
    March 2021
30. FIGTREE GA, Vernon ST, Hadziosmanovic N, Sundstrom J, et al
    Mortality in STEMI patients without standard modifiable risk factors: a sex-disaggregated analysis of SWEDEHEART registry data.
    Lancet. 2021;397:1085-1094.
    

    >> Share

    
    February 2021
31. LANGLEY RE, Gilbert DC, Duong T, Clarke NW, et al
    Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programme.
    Lancet. 2021;397:581-591.
    

    >> Share

    
    January 2021
32. VADUGANATHAN M, Fonarow GC, McMurray JJV, Solomon SD, et al
    Considering dose in pharmacological therapies for heart failure - Authors' reply.
    Lancet. 2021;397:275.
    

    >> Share

    
    
33. SEEDAT Z, Itty K
    Considering dose in pharmacological therapies for heart failure.
    Lancet. 2021;397:274-275.
    

    >> Share

    
    November 2020
34. PONIKOWSKI P, Kirwan BA, Anker SD, McDonagh T, et al
    Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial.
    Lancet. 2020 Nov 12. pii: S0140-6736(20)32339.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share